Company · Healthtech & Bio

Ona Therapeutics

ona-therapeutics.com ↗ ·Barcelona ·Series B

Ona Therapeutics is a Barcelona-based clinical-stage biotech developing first-in-class antibody-drug conjugates (ADCs) and antibodies against advanced and treatment-resistant solid tumours, built on research into metastasis-initiating cells and lipid metabolism. Spun out of IRB Barcelona and ICREA in 2019, it runs three internal ADC programmes (ONA-255 for breast cancer and solid tumours, ONA-389, and dual-payload ONA-418). It raised a €30M Series A in 2020 and an oversubscribed €74.2M (~$86.6M) Series B in June 2026, one of the largest life-sciences rounds in Catalonia.

Founded
2019
Founders
2
News
1
Rounds
1
Investors
10
SectorsBiotech, Oncology, Antibody-Drug Conjugates, Pharmaceuticals, Life Sciences Start-up MapHealthtech & Bio › Drug discovery & therapeutics developers

Profile updated 17 Aug 2026

Founders

Salvador Aznar Benitah
Scientific Co-founder (ICREA Research Professor, IRB Barcelona)
—
Valerie Vanhooren
Co-founder & Chief Executive Officer

Global models

No comparables on record yet.

Investors 10

Funding rounds 1

Series B · €74.2M
IRB Barcelona spin-out closed an oversubscribed €74.2M Series B co-led by Columbus and Mérieux to take its first-in-class antibody-drug conj…
2026-06-04

News & media 1

PublishedArticle
2026-09-10 Spain's top-funded tech companies in H1 2026 ↗
Tech.eu
Start typing to search across everything.
↑↓ navigate↵ openesc close